You are here: Industry Insights > Bristol Myers Squibb

News List

Drug pricing, reimbursement constraints leading impediments to industry growth in 2021: GlobalData expresspharma
January 11, 2021
In 2021, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData, a data and analytics company.
Bristol Myers Squibb get EC approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with chemotherapy for metastatic NSCLC expresspharma
November 09, 2020
Opdivo plus Yervoy-based combinations now indicated in the EU for three different advanced cancer types: non-small cell lung cancer, melanoma and renal cell carcinoma.
Bristol Myers Squibb’s psoriasis med hits the mark in phase III pharmatimes
November 06, 2020
Bristol Myers Squibb’s tyrosine kinase 2 (TYK2) inhibitor deucravacitinib outperformed Amgen’s Otezla in a phase III psoriasis study, the pharma company revealed yesterday.
Iontas Enters Licensing Agreement with Bristol Myers Squibb contractpharma
October 16, 2020
Iontas Limited, a biotechnology company focused on antibody discovery and technology development, has entered into a licensing agreement with Bristol Myers Squibb Company regarding the company’s proprietary mammalian display.
Bristol Myers Squibb presents data from True North trial of Zeposia (ozanimod) for ulcerative colitis expresspharma
October 12, 2020
Both primary and all key secondary efficacy endpoints showed statistically significant improvements with oral Zeposia versus placebo at Week 10 and Week 52.
Bristol Myers Squibb’s Opdivo shows benefit in oesophageal cancers pharmatimes
September 23, 2020
Bristol Myers Squibb’s Opdivo (nivolumab) demonstrated promise in a phase III CheckMate-577 trial involving patients with oesophageal or gastroesophageal junction (GEJ) cancers who had previously receiving neoadjuvant chemoradiation therapy (CRT) and ...
CHMP advises approval for Bristol Myers Squibb’s Opdivo plus Yervoy with chemo for metastatic NSCLC expresspharma
September 21, 2020
The European Commission will now review the CHMP recommendation.
Bristol Myers Squibb to acquire Forbius expresspharma
August 26, 2020
Forbius’s lead TGF-beta asset, AVID200, is an isoform-selective TGF-beta inhibitor, currently in Phase 1 for oncology and fibrosis.
Agios, Royalty Pharma Announce Purchase Agreement for IDHIFA Royalty americanpharmaceuticalreview
June 23, 2020
Agios Pharmaceuticals has sold its tiered, sales-based royalty rights on worldwide net sales of Bristol Myers Squibb’s IDHIFA® (enasidenib) ...
Ubiquigent Continues Collaboration with Bristol Myers Squibb contractpharma
June 18, 2020
Supports development of novel DUB inhibitors for patients.

Previous page 1 2 3 4 Next page